NDA 218592 is the FDA application for PIXCLARA (floretyrosine F-18). The FDA's Orange Book lists the applicant of record as TELIX PHARMACEUTICALS US INC and the first approval on it as Sep 11, 2026. Code names used in development: TLX101-Px, TLX101-CDx. Owner today: Telix Pharmaceuticals Limited (ASX/Nasdaq: TLX).
Page updated Nov 19, 2026. FDA records: Drugs@FDA NDA 218592 · Orange Book NDA 218592
| Brand name (FDA) | PIXCLARA Orange Book trade name: PIXCLARA |
|---|---|
| Active ingredient (FDA) | FLORETYROSINE F-18 |
| Code name | TLX101-Px Source: Telix Pharmaceuticals press release, Sep 14, 2026 “Pixclara (TLX101-Px) is also the subject of a Phase 3 registrational study for potential indication expansion” |
| Code name | TLX101-CDx Source: Telix Pharmaceuticals press release, Oct 24, 2024 “TLX101-CDx (Pixclara) is a PET imaging agent, which has been granted fast track and orphan drug” |
| FDA applicant of record | TELIX PHARMACEUTICALS US INC FDA Orange Book data files as of Nov 13, 2026 |
|---|---|
| Owner today | Telix Pharmaceuticals Limited (TLX) Source: Telix Pharmaceuticals press release, Sep 14, 2026 “(ASX: TLX, NASDAQ: TLX, “Telix”) today announces that the United States (U.S.) Food and Drug Administration (FDA)” |
| No. | Trade name | Form; route | Strength | Approved |
|---|---|---|---|---|
| 001 | PIXCLARA | SOLUTION;INTRAVENOUS | 5-300mCi/ML | Sep 11, 2026 |
Drug page: /drug/pixclara
Orange Book data: FDA Orange Book data files, as of Nov 13, 2026. Approval dates are the FDA's dates for each product; a later supplement (a new use) does not change them.